CA-PROGENITY-INC
Progenity Inc., a private biotechnology company, announced today the completion of a privately placed $125 million Series B financing comprising equity and debt. The financing was led by a fund managed by an existing investor, Athyrium Capital Management.
“We are grateful for the continued support of our existing investors, and we welcome the new investors to the Progenity team,” said Harry Stylli, Executive Chairman and Founder, Progenity Inc. “The net proceeds from this financing will be used to accelerate development of our transformative gastrointestinal (GI) platform targeting diagnostics and therapeutics for the GI tract, including precision molecular diagnostics tools, precision therapeutics, microbiome analytics, and consumer health nutrition. In addition, the proceeds will be used to enhance our menu and service offerings to our physician clients in the Prenatal and broader Women’s Health market on a national scale. We shall continue to invest in new assets to strengthen our internal innovation and commercial efforts.”
“We are excited to continue to support Progenity's growth in patient-focused diagnostics and therapeutics,” said Jeffrey A. Ferrell, Managing Partner, Athyrium Capital Management. “The platform the team has built is a testament to the Company's vision in Women's Health and the promise of their growing Oncology and Gastroenterology franchises. With this financing, we believe that the company will be well capitalized to execute on its internal pipeline and business development opportunities.”
About Progenity
Progenity is a biotechnology company with a market-leading presence in Women’s Health molecular testing and a pipeline of proprietary tests and therapeutic applications under development. Progenity has a portfolio of innovative technologies and tests for pre-eclampsia, genetic carrier testing, inheritable cancer genetics, liquid biopsy and noninvasive prenatal testing (NIPT), all designed to support clinicians in providing excellent patient care. Progenity is using a transformational platform to target therapeutic agents to the GI tract and has the potential to deliver proteins orally. Further, the company is developing a portfolio of powerful precision molecular diagnostics, such as small intestine bacterial overgrowth (SIBO), microbiome analytics for both the upper and lower GI tract, and consumer health nutrition applications. With a focus on GI diseases that affect over one third of all Americans, including irritable bowel syndrome, fatty liver disease, inflammatory bowel disease, and gastrointestinal cancers; Progenity’s outpatient diagnostic and therapeutic approaches are designed to provide compelling new medical management options. For more information on Progenity’s Prenatal and Women’s Health business, visit progenity.com .
About Athyrium Capital Management
Athyrium Capital Management, LP (“Athyrium”) is a specialized asset management company formed in 2008 to focus on investment opportunities in the global healthcare sector. As of September 30, 2017, Athyrium had over $3.5 billion of assets under management. The Athyrium team has substantial investment experience in the healthcare sector across a wide range of asset classes including public equity, private equity, fixed income, royalties, and other structured securities. Athyrium invests across all healthcare verticals, including biopharma, medical devices and products, and healthcare focused services. The team partners with management teams to implement creative financing solutions to companies’ capital needs. For more information, please visit www.athyrium.com .
View source version on businesswire.com: http://www.businesswire.com/news/home/20171107005944/en/
Contact:
Media Contact:
CG Life for Progenity
Erik
Clausen, (781) 608-7091
or
Investor
Contact:
Progenity Inc.
Sumit Aggarwal, CFO, (760)
494-1755
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Lantern Appoints Jeff Williams as Chief Product Officer, Marking Expansion into the US2.9.2025 20:03:00 CEST | Press release
Lantern, the data intelligence platform for private markets, today announced the appointment of Jeff Williams as its first Chief Product Officer (CPO). Based in the United States, Jeff’s appointment marks a major milestone as Lantern establishes its presence in North America, to support its rapidly growing global client base. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250902271705/en/ Jeff Williams, Lantern Chief Product Officer Jeff brings more over 15 years’ experience at the intersection of private markets and technology. Most recently, he served as Chief Strategy Officer at Altvia, where he played a central role in shaping product strategy, guiding product launches, and driving growth. Edward Moore, Founder and CEO of Lantern, commented: “Jeff has a rare blend of product expertise and deep knowledge of private markets. He’s led product strategy through periods of intense growth and complexity, and his experience will
Coherent Solutions secures strategic investment from IceLake Capital to fuel global growth2.9.2025 18:48:00 CEST | Press release
Coherent Solutions, a global digital solutions engineering firm, has secured a strategic investment from IceLake, a leading private equity investor specializing in partnering with high-growth business services organizations. The partnership will accelerate Coherent Solutions’ global expansion and solution offerings, advancing its mission to deliver measurable digital value creation for clients worldwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250902336956/en/ Coherent Solutions has secured a strategic investment from IceLake, advancing its mission to deliver measurable digital value creation for clients worldwide. This year marks Coherent Solutions’ 30th anniversary. Since its founding in 1995, the company has partnered with some of the world’s largest brands and most ambitious growth companies to design, develop, and launch sophisticated digital platforms and solutions. “The partnership with IceLake is a strong vote
Proteintech Launches “Able” AI – A First-of-Its-Kind Tool to Accelerate Scientific Discovery2.9.2025 17:18:00 CEST | Press release
Proteintech, a global leader in antibodies and life science solutions, today announced the launch of Able AI, a first-of-its-kind artificial intelligence tool that is now available on ptglab.com. Finding the most suitable antibodies from the vast pool of potential products is a challenge. Able helps scientists pinpoint the right antibody based on their research needs, while also providing all relevant information and associated scientific knowledge. In addition, it offers detailed guidance on product specific experimental procedures, significantly reducing the time spent on planning and product selection. This release follows Proteintech’s successful introduction of 3D Epitope Mapping earlier this year, which advanced researchers’ ability to visualize antibody binding sites through experimental and AI-powered modelling. This capability reduces guesswork and trial-and-error, enabling scientists to better design experiments and develop products with greater precision. “Able represents th
MSP Sports Capital Confirms Sale of its Holdings in McLaren Racing to McLaren Group Limited2.9.2025 17:02:00 CEST | Press release
As announced earlier today, McLaren Group Limited has completed the purchase of MSP Sports Capital’s equity interest in McLaren Racing, including its Formula 1 Team. The transaction will enable Bahrain Mumtalakat Holding Company and CYVN Holding, an advanced mobility operator and investment vehicle based in Abu Dhabi, to increase their share and assume full ownership of the iconic British motor racing business. Mumtalakat will continue as majority shareholder with CYVN Holdings owning a non-controlling stake. MSP’s investment came at a pivotal moment in the business, providing vital capital that contributed to the company’s efforts in stabilizing business operations during the COVID-19 pandemic, funding infrastructure upgrades, and retaining and recruiting world-class talent. Over the last five years, with the support received from its shareholders, McLaren has returned to the front of the Formula 1 grid, rebuilt its competitiveness across multiple racing series, and enhanced its long
Textron Aviation Expands ProAdvantage Portfolio With Launch of ProParts+ for Cessna Citation 525 Series2.9.2025 17:00:00 CEST | Press release
Textron Aviation Inc., a Textron Inc. (NYSE: TXT) company, today announced the launch of ProParts+, a new addition to the company’s industry-leading ProAdvantage support programs, designed specifically for Cessna Citation 525 series operators. ProParts+ builds on the trusted foundation of the ProParts program, offering expanded coverage to address key customer identified priorities and enhance operational predictability. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250902524070/en/ Textron Aviation announced the launch of ProParts+, a new addition to the company’s industry-leading ProAdvantage support programs, designed specifically for Cessna Citation 525 series operators. (Textron Aviation) “Expanding our ProAdvantage portfolio with ProParts+ reflects our continued investment in the long-term support of the Citation 525 Series,” said Brad White, senior vice president, Global Parts Distribution. “ProParts+ is a direct res
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom